Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System.
Sign Up to like & getrecommendations! Published in 2017 at "Vaccine"
DOI: 10.1016/j.vaccine.2017.08.047
Abstract: On January 16, 2013, the Food and Drug Administration approved recombinant hemagglutinin influenza vaccine (RIV3) (Spodoptera frugiperda cell line; Flublok), which is the first completely egg-free flu vaccine licensed in the United States. To improve… read more here.
Keywords: adverse event; influenza vaccine; vaccine adverse; vaccine ... See more keywords